

FINANCIAL STATEMENTS (Un-Audited)
For the period from 01.01.2014 to 30.09.2014



THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

House No. 41, Road No. 10/A, Dhanmondi ,

Dhaka-1209, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

House # 41, Road # 10/A, Dhanmondi, Dhaka-1209


As per requirement of the Bangladesh Securities & Exchange Commission's (BSEC) Notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009, The IBN SINA Pharmaceutical Industry Ltd. is pleased to submit the un-audited Financial Statements for the nine months period ended 30th September, 2014.

STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 30th September, 2014

				Amount in Taka	
				As at	As at
				30.09.2014	31.12.2013
Notes					
ASSETS:					
Non-Current Assets:					
			699,016,339	718,695,370	
	02	Property, Plant and Equipment	420,717,214	383,646,483	
	03	Investment in Marketable Securities (Fair Value)	278,299,125	335,048,887	
			379,497,124	377,736,738	
Current Assets :					
	04	Inventories	140,774,299	136,650,467	
		Sundry Debtors	3,422,156	3,538,212	
	05	Advances, Deposits & Prepayments	128,901,625	117,849,701	
	06	Cash & Cash Equivalents	106,399,044	119,698,358	
TOTAL ASSETS			<u>1,078,513,463</u>	<u>1,096,432,108</u>	
SHAREHOLDERS' EQUITY AND LIABILITIES:					
Shareholders' Equity:					
		Share Capital	213,840,000	194,400,000	
	03	Gain on Marketable Securities (Unrealized)	240,842,043	310,156,938	
		Tax Holiday Reserve	4,392,110	4,392,110	
	07	Retained Earnings	188,184,264	195,656,433	
Non-Current Liabilities			87,216,284	68,398,551	
Deferred Tax Liability			1,881,585	5,243,267	
Current Liabilities:					
	10	Bank Finance & Other Credits	140,920,529	134,708,099	
	11	Creditors and Accruals	201,236,648	183,476,710	
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES			<u>1,078,513,463</u>	<u>1,096,432,108</u>	

Dated, Dhaka
October 23, 2014



(Md. Jasim Uddin, ACA)
Chief Financial Officer



(Prof. A.N.M.A. Zaher)
Managing Director

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF COMPREHENSIVE INCOME (Un-Audited)
For the period from January to September 30, 2014

Amount in Taka				
Notes	1st Jan 2014 to 30th Sept 2014	1st Jan 2013 to 30th Sept 2013	1st July 2014 to 30th Sept 2014	1st July 2013 to 30th Sept 2013
Turnover and Other income	1,970,236,676	1,569,928,882	725,826,012	570,714,391
Cost of goods sold	<u>1,187,726,972</u>	<u>946,352,729</u>	<u>436,103,575</u>	<u>343,432,913</u>
Gross Profit	782,509,704	623,576,153	289,722,437	227,281,478
Operating Expenses:				
Administrative expenses	45,884,652	43,800,794	9,988,288	16,834,264
Selling & Distribution expenses	14 <u>650,419,354</u>	<u>514,721,842</u>	<u>248,517,850</u>	<u>185,569,305</u>
	696,304,006	558,522,636	258,506,138	202,403,569
Operating Profit	86,205,698	65,053,517	31,216,299	24,877,909
Financial Charges	3,355,413	4,037,898	2,100,746	1,345,966
	82,850,285	61,015,619	29,115,553	23,531,943
Workers' P.P. Fund & Welfare Fund	3,945,252	2,905,506	1,386,455	1,120,569
Net Profit before tax -	78,905,033	58,110,113	27,729,098	22,411,374
Less: Income tax expenses				
Current tax	21,698,884	15,980,281	7,625,502	6,163,128
Deferred tax	09 <u>(3,361,682)</u>	<u>(3,265,079)</u>	<u>(3,155,599)</u>	<u>(3,390,912)</u>
	18,337,202	12,715,202	4,469,903	2,772,216
Net Profit after tax	60,567,831	45,394,911	23,259,195	19,639,158
Other Comprehensive Income:				
Gain/(Loss) on Marketable Securities	03 <u>(69,314,895)</u>	<u>(5,453,918)</u>	<u>(4,327,092)</u>	<u>(21,101,309)</u>
(Unrealized)	<u>(8,747,064)</u>	<u>39,940,993</u>	<u>18,932,103</u>	<u>(1,462,151)</u>
Earnings per share(EPS)(2013: restated)	<u>2.83</u>	<u>2.12</u>	<u>1.09</u>	<u>0.92</u>

Dated , Dhaka
October 23,2014


(Md. Jasim Uddin, ACA)
Chief Financial Officer


(Prof. A.N.M.A. Zaher)
Managing Director

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF CASH FLOWS (Un-Audited)

For the period from January to September 30, 2014

	Amount in Taka	
	1st Jan 2014 to 30th Sept 2014	1st Jan 2013 to 30th Sept 2013
Cash Flow From Operating Activities:		
Collection from customers & others	1,959,999,982	1,562,121,346
Payment to creditors for expenses	(1,843,248,110)	(1,483,598,196)
Income tax paid	(21,308,233)	(24,977,387)
Financial charges	(3,355,413)	(4,037,898)
Miscellaneous income	553,800	1,269,724
Net cash provided by operating activities	92,642,026	50,777,589
Cash Flow From Investing Activities:		
Purchase of fixed assets	(63,066,323)	(37,233,767)
Investment	(12,565,133)	(4,990,699)
Dividend income	7,659,649	6,498,840
Profit from bank deposits & investment	1,657,324	763,701
Net cash used in investing activities	(66,314,483)	(34,961,925)
Cash Flow From Financing Activities:		
Payment of dividend	(33,843,762)	(1,911,516)
Long term finance received/(paid) from bank	8,316,257	-
Short term finance received/(paid) from bank	(4,490,693)	(23,538,153)
Changes in other finance	(9,608,659)	(7,143,978)
Net cash flow from financing activities	(39,626,857)	(32,593,647)
Increase/(decrease) in cash and cash equivalents	(13,299,314)	(16,777,983)
Cash and cash equivalents at the opening	119,698,358	107,178,866
Cash and cash equivalents at the closing	<u>106,399,044</u>	<u>90,400,883</u>

Dated, Dhaka

October 23, 2014


(Md. Jasim Uddin, ACA)
Chief Financial Officer


(Prof. A.N.M.A. Zaher)
Managing Director

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)
For the period from January to September 30, 2014

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2013	162,000,000	4,392,110	329,744,761	165,179,622	661,316,493
Dividend for the year, 2012	32,400,000	-		(56,700,000)	(24,300,000)
Total Comprehensive Income/(Loss)-2013	-	-	(19,587,823)	87,176,811	67,588,988
Balance as at 1st January, 2014	194,400,000	4,392,110	310,156,938	195,656,433	704,605,481
Total Comprehensive Income/(Loss) for the period ended 30th Sept, 2014			(69,314,895)	60,567,831	(8,747,064)
Dividend for the year, 2013 (Cash-25%)				(48,600,000)	(48,600,000)
Dividend for the year, 2013 (Stock-10%)	19,440,000			(19,440,000)	-
Balance as at 30th September, 2014	213,840,000	4,392,110	240,842,043	188,184,264	647,258,417

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)
For the period from January to September 30, 2013

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2013	162,000,000	4,392,110	329,744,761	165,179,622	661,316,493
Dividend for the year, 2012 (Cash-15%)	-	-	-	(24,300,000)	(24,300,000)
Dividend for the year, 2011 (Stock-20%)	32,400,000	-	-	(32,400,000)	-
Total Comprehensive Income/(Loss) for the period ended 30th Sept., 2012	-	-	(5,453,918)	45,394,911	39,940,993
Balance as at 30th September, 2013	194,400,000	4,392,110	324,290,843	153,874,533	676,957,486

Dated, Dhaka
October 23, 2014


(Md. Jasim Uddin, ACA)
Chief Financial Officer


(Prof. A.N.M.A. Zaher)
Managing Director